Vyndaqel access in the United Arab Emirates: the EDE named-patient pathway

Last reviewed 2026-05-12 by the Reserve Meds clinical and regulatory team. This page combines the UAE country research module with the Vyndaqel drug module to describe the path families actually walk.

Quick orientation

Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are oral transthyretin (TTR) tetramer stabilisers developed by Pfizer (originally FoldRx). The US Food and Drug Administration approved tafamidis in May 2019 for transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, covering both wild-type ATTR-CM and hereditary (variant) ATTR-CM. Vyndaqel is given as four 20 mg capsules of tafamidis meglumine daily (80 mg daily total). Vyndamax is the bioequivalent free-acid formulation given as one 61 mg capsule daily, which is the schedule most cardiomyopathy teams prefer for adherence. Tafamidis stabilises the TTR tetramer, slowing dissociation into the misfolded monomers that aggregate into amyloid fibrils in cardiac tissue. The ATTR-ACT trial demonstrated reduced all-cause mortality and reduced cardiovascular-related hospitalisation versus placebo in ATTR-CM patients on tafamidis. Reserved for you.

Why UAE patients need Vyndaqel via a named-patient pathway

Transthyretin amyloid cardiomyopathy is increasingly recognised across the UAE adult cardiology population. The recognition shift over the past decade has been driven by the availability of bone scintigraphy (technetium-pyrophosphate or DPD scan) as a non-invasive diagnostic tool, the genetic testing infrastructure that identifies hereditary TTR variants, and the practice change in cardiology to consider ATTR-CM in older adults presenting with unexplained left ventricular hypertrophy or heart failure with preserved ejection fraction. Local registries and regional case series document a meaningful UAE patient population with both wild-type and variant ATTR-CM.

The diagnostic pathway is well established. The treatment access pathway is the question. Tafamidis is not consistently held in UAE federal stock at the level a chronic cardiology medication would warrant. When the cardiomyopathy team has confirmed the ATTR-CM diagnosis (typically by bone scintigraphy with grade 2 or 3 cardiac uptake plus the absence of a monoclonal gammopathy, or by endomyocardial biopsy), the EDE named-patient pathway is the established route. The competing US-approved option for hereditary ATTR amyloidosis is patisiran (Onpattro) or vutrisiran (Amvuttra), both RNA interference therapeutics. The clinical positioning of tafamidis (oral, daily, indefinite) versus the RNA interference therapeutics (intravenous or subcutaneous, scheduled, indefinite) rests with the cardiomyopathy team.

The EDE / MoHAP named-patient pathway applied to Vyndaqel

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered or not stocked locally is the unregistered-medicine import permit, administered through the Emirates Drug Establishment (EDE) at ede.gov.ae. The EDE took over 44 core services from MoHAP under Federal Decree-Law No. 38 of 2024. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority such as the US FDA and a locally registered alternative is not suitable.

For Vyndaqel or Vyndamax, the clinical justification packet is anchored on the diagnostic confirmation. The treating cardiologist (typically with a cardiomyopathy or heart failure subspecialty) documents the diagnosis (transthyretin amyloid cardiomyopathy, wild-type or hereditary, with the diagnostic basis specified: bone scintigraphy with grade 2 or 3 cardiac uptake plus the absence of monoclonal gammopathy on serum and urine immunofixation and serum free light chains, or endomyocardial biopsy with mass spectrometry typing). For hereditary cases, the TTR gene variant is identified. The cardiomyopathy team documents the clinical staging (New York Heart Association functional class, NT-proBNP, troponin, eGFR), the planned formulation (Vyndaqel four-capsule schedule or Vyndamax single-capsule schedule), and the patient's commitment to lifelong therapy.

A complete EDE application for Vyndaqel or Vyndamax typically includes the cardiologist's clinical justification letter, the bone scintigraphy or biopsy report, the monoclonal gammopathy screen, the genetic test report where applicable, the treating physician's MoHAP, DHA, DoH, or Sharjah Health Authority licence verification, an anonymised patient identifier, full product details (Vyndaqel 20 mg capsules at four capsules daily or Vyndamax 61 mg capsule daily), the destination dispensing pharmacy name with licence number and pharmacy in charge, and the patient informed consent. Approval timelines for routine cases are 5 to 15 business days.

Where Vyndaqel gets dispensed in the UAE

Vyndaqel and Vyndamax are oral capsules with standard ambient storage at 20 to 25 degrees Celsius. The dispensing site is the outpatient pharmacy attached to the treating cardiology service. The most natural dispensing sites are the cardiomyopathy and heart failure services at Cleveland Clinic Abu Dhabi (the Heart and Vascular Institute), the Heart Hospital at Sheikh Khalifa Medical City, American Hospital Dubai, Mediclinic City Hospital in Dubai Healthcare City, and NMC Royal Hospital in Khalifa City. The dispensing cadence is typically structured at 3-month intervals to optimise the per-month delivered logistics cost for a chronic-supply medication.

Real cost picture for Vyndaqel in the UAE

The US wholesale acquisition cost for Vyndaqel or Vyndamax is approximately USD 19,000 to 22,000 per month, translating to approximately AED 70,000 to 80,000 monthly at the 3.67 peg. The figure is the drug acquisition cost only and is comparable between the four-capsule Vyndaqel schedule and the single-capsule Vyndamax schedule.

All-in delivered cost stacks the drug acquisition, ambient international logistics (USD 400 to 700 per shipment, typically scheduled at 3-month intervals), EDE handling and customs (USD 300 to 600 per case), the dispensing pharmacy fee, and the Reserve Meds concierge coordination fee. Insurance in the UAE handles ATTR cardiomyopathy therapies case by case. Pre-authorisation is the norm. Thiqa, administered by Daman, has the broadest specialty coverage for UAE nationals in Abu Dhabi. We do not promise coverage.

Typical timeline for Vyndaqel in the UAE

The EDE permit processes in 5 to 15 business days for a routine submission with a clear ATTR-CM diagnosis and a documented cardiomyopathy team assessment. International logistics for an ambient-shipped oral medication adds 3 to 7 business days. Customs clearance is typically 1 to 3 business days. A patient who completes the documentation in week one typically receives the first prescription in week three to week five. Subsequent supply is at 3-month intervals.

What your physician needs to provide

The clinical justification letter for a Vyndaqel or Vyndamax EDE submission is structured around the ATTR-CM diagnostic pathway. The treating cardiologist's letter typically addresses the diagnosis (ATTR-CM, wild-type or hereditary, with diagnostic basis), the monoclonal gammopathy screen result, the genetic test report for hereditary cases with the TTR variant identified, the clinical staging, the prior heart failure regimen and tolerance, the rationale for tafamidis (ATTR-ACT trial evidence, oral once-daily schedule, established mortality and hospitalisation reduction), and the chosen formulation (Vyndaqel four capsules daily or Vyndamax single capsule daily). The letter references the Pfizer US label.

The treating physician's licence must be in active standing in the emirate of the dispensing facility (MoHAP for the Northern Emirates, DHA for Dubai, DoH for Abu Dhabi and Al Ain, Sharjah Health Authority for Sharjah). The patient signs informed consent reflecting the lifelong nature of therapy.

Pharmacovigilance considerations

Tafamidis is exceptionally well tolerated by the standards of cardiology specialty therapies. The adverse-event profile in the ATTR-ACT trial was comparable to placebo across the major categories. Drug-drug interactions are limited: tafamidis is a BCRP inhibitor and the US label provides specific guidance on concurrent BCRP substrates such as methotrexate, rosuvastatin, and imatinib. The treating cardiology team monitors heart failure progression with the standard schedule (NT-proBNP, echocardiography, NYHA functional class). The therapy is lifelong; the team frames it as part of the chronic cardiology regimen rather than a course of treatment. Adverse events identified by the treating team route to Pfizer's safety reporting channel and to the EDE post-market surveillance address.

Common questions about Vyndaqel in the UAE

Vyndaqel or Vyndamax, what's the difference? Vyndaqel is tafamidis meglumine, given as four 20 mg capsules daily for a total of 80 mg daily. Vyndamax is the bioequivalent free-acid form of tafamidis, given as one 61 mg capsule daily. Most cardiomyopathy teams prefer Vyndamax for adherence. The two are clinically interchangeable at the FDA-approved doses.

Why tafamidis rather than patisiran, vutrisiran, or inotersen? Tafamidis is a transthyretin tetramer stabiliser and is FDA-approved for ATTR-CM in adults (wild-type and hereditary). The RNA interference therapeutics patisiran (Onpattro, intravenous every 3 weeks) and vutrisiran (Amvuttra, subcutaneous every 3 months) are FDA-approved for hereditary ATTR amyloidosis with polyneuropathy. Vutrisiran also holds an FDA-approved indication for ATTR-CM as of 2024. The clinical positioning rests on the disease phenotype (cardiomyopathy-dominant versus polyneuropathy-dominant versus mixed), the patient's preference for oral versus infusion, and the cardiomyopathy team's experience. The clinical choice rests with the treating cardiology and amyloidosis team.

Will Daman, Thiqa, or my private insurer cover this? Each insurer assesses ATTR-CM therapies case by case. Pre-authorisation is the norm. Thiqa has the broadest specialty coverage in Abu Dhabi. We do not promise coverage.

Is Vyndaqel a controlled substance? No. Vyndaqel and Vyndamax are not DEA scheduled substances.

Is this treatment lifelong? Yes. Tafamidis slows the progression of amyloid deposition; it does not remove existing deposits. The cardiomyopathy team treats it as a lifelong part of the chronic regimen.

What patients and families ask when they first call

"How does the case actually start?" The patient, family, or treating cardiologist contacts Reserve Meds through the waitlist form. Within 24 to 48 hours, a coordinator confirms eligibility (the ATTR-CM diagnostic confirmation is the central screening question), sends the documentation kit to the physician, and outlines the EDE submission sequence. No payment is taken at this stage.

"What if family members have a hereditary TTR variant?" Hereditary ATTR amyloidosis follows an autosomal dominant inheritance pattern with variable penetrance and age of onset. First-degree relatives of a hereditary ATTR patient are candidates for genetic counselling and testing. Asymptomatic carriers are followed clinically and are not initiated on tafamidis until cardiomyopathy or polyneuropathy criteria are met. The treating amyloidosis team coordinates the family screening.

"What if heart failure worsens despite tafamidis?" Tafamidis slows disease progression but does not arrest it in every patient. Patients on tafamidis who experience progressive heart failure receive standard heart failure management (loop diuretic optimisation, fluid status management, atrial fibrillation rhythm or rate control where applicable) coordinated by the cardiomyopathy team. The team may also consider whether the patient is a candidate for adding or switching to an RNA interference therapeutic.

"Is there an upper limit on how late in the disease tafamidis is started?" The US label and the ATTR-ACT trial protocol restricted enrollment to NYHA class I-III patients. Class IV patients were not enrolled. In practice, most cardiomyopathy teams initiate tafamidis at the earliest confirmed diagnosis where the patient is functional and a meaningful runway of slowing disease progression is in view. The treating team makes this call.

Where Reserve Meds fits in Vyndaqel cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating cardiologist or amyloidosis team, the EDE, or the dispensing pharmacy. For a Vyndaqel or Vyndamax case, our work is the regulatory documentation assembly, the US-side procurement coordination with the Pfizer specialty distributor, the logistics (typically scheduled at 3-month intervals for chronic supply), the customs handoff, and a single named coordinator for the patient through onboarding and the recurring supply. Reserved for you.

Documentation kit for the treating cardiology team

The documentation kit Reserve Meds sends the treating cardiologist or amyloidosis team after a waitlist confirmation contains the EDE clinical-justification letter template tailored to ATTR cardiomyopathy with the diagnostic pathway documented, the bone scintigraphy or biopsy report capture sheet, the monoclonal gammopathy screen capture sheet, the genetic test report for hereditary cases with the TTR variant identified, the clinical staging template (NYHA class, NT-proBNP, troponin, eGFR), the formulation selection guide (Vyndaqel four-capsule daily or Vyndamax single-capsule daily), the patient informed consent template covering the lifelong nature of therapy, the dispensing pharmacy intake checklist for the 3-month chronic supply cadence, the heart failure surveillance template, and the family genetic-counselling referral guide where applicable. The kit is built so the cardiomyopathy team focuses on the patient and family conversation that anchors the chronic ATTR regimen.

Next step

If a treating cardiologist in the UAE has confirmed the ATTR-CM diagnosis and is weighing tafamidis, the waitlist is the first step. We respond within 24 to 48 hours with an eligibility confirmation and a documentation kit for the physician.

Join the Vyndaqel waitlist

Reserved for you.

Related

• Vyndaqel clinical resource
• Transthyretin amyloidosis
• United Arab Emirates country page
• Named-patient pathway overview

Sources

1. FDA approval, Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis), Pfizer (originally FoldRx), approval May 2019 for ATTR cardiomyopathy in adults.
2. UAE Federal